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AbstrAct
Objectives To evaluate potential return on investment 
of the National Health Service Diabetes Prevention 
Programme (NHS DPP) in England and estimate which 
population subgroups are likely to benefit most in terms of 
cost-effectiveness, cost-savings and health benefits.
Design Economic analysis using the School for Public 
Health Research Diabetes Prevention Model.
setting England 2015–2016.
Population Adults aged ≥16 with high risk of type 2 
diabetes (HbA1c 6%–6.4%). Population subgroups defined 
by age, sex, ethnicity, socioeconomic deprivation, baseline 
body mass index, baseline HbA1c and working status.
Interventions The proposed NHS DPP: an intensive 
lifestyle intervention focusing on dietary advice, physical 
activity and weight loss. Comparator: no diabetes 
prevention intervention.
Main outcome measures Incremental costs, savings and 
return on investment, quality-adjusted life-years (QALYs), 
diabetes cases, cardiovascular cases and net monetary 
benefit from an NHS perspective.
results Intervention costs will be recouped through NHS 
savings within 12 years, with net NHS saving of £1.28 
over 20 years for each £1 invested. Per 100 000 DPP 
interventions given, 3552 QALYs are gained. The DPP is 
most cost-effective and cost-saving in obese individuals, 
those with baseline HbA1c 6.2%–6.4% and those aged 
40–74. QALY gains are lower in minority ethnic and low 
socioeconomic status subgroups. Probabilistic sensitivity 
analysis suggests that there is 97% probability that the 
DPP will be cost-effective within 20 years. NHS savings 
are highly sensitive to intervention cost, effectiveness and 
duration of effect.
conclusions The DPP is likely to be cost-effective and 
cost-saving under current assumptions. Prioritising obese 
individuals could create the most value for money and 
obtain the greatest health benefits per individual targeted. 
Low socioeconomic status or ethnic minority groups may 
gain fewer QALYs per intervention, so targeting strategies 
should ensure the DPP does not contribute to widening 
health inequalities. Further evidence is needed around the 
differential responsiveness of population subgroups to the 
DPP.
IntrODuctIOn
Type 2 diabetes is a major public health 
priority in the UK. Currently there are 
>2.9 million people with diabetes in England1 
and estimated to be a further 5 million at high 
risk of developing the disease.2 Diabetes is 
estimated to directly cost the National Health 
Service (NHS) in England about £5.6 billion 
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Research
strengths and limitations of this study
 ► The study uses the School for Public Health 
Research  (SPHR) Diabetes Prevention Model, 
which synthesises a broad range of evidence from 
published data about type 2 diabetes risk factors 
and the complex disease progression pathways that 
lead from a diabetes diagnosis.
 ► The individual patient-level model structure allows 
the heterogeneity present within the population to 
be modelled, enabling detailed subgroup analysis.
 ► The National Health Service (NHS) Diabetes 
Prevention Programme  (DPP) has recently begun 
national implementation and direct data collection 
on its effectiveness in practice in England has not 
yet been obtained; therefore, the analysis assumes 
that effectiveness will be similar to that obtained in 
pragmatic trials of intensive lifestyle interventions 
aimed at preventing type 2 diabetes, while also 
undertaking sensitivity analysis around this 
assumption.
 ► The analysis uses a comparator of ‘no NHS DPP 
intervention’, which does not fully represent the 
current situation where some localities do have 
programmes for high-risk individuals. These 
were not modelled due to limited evidence and 
heterogeneity of intervention implementation 
between localities.
 ► Data about the long-term effectiveness of lifestyle 
interventions and the differential response of 
population subgroups to such interventions are 
limited. Further research is required to inform these 
parameters.
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per year,3 of which most contributes to treating compli-
cations of the disease such as amputation, blindness, 
kidney failure and cardiovascular disease (CVD). To help 
tackle this problem, Public Health England (PHE), NHS 
England and Diabetes UK are together implementing 
the NHS Diabetes Prevention Programme (DPP).4 The 
NHS DPP consists of intensive lifestyle management 
programmes aimed at those at high risk of diabetes due 
to impaired glucose regulation (IGR), defined as HbA1c 
6%–6.4% (42–47 mmol/mol) or fasting plasma glucose 
of 5.5–6.9 mmol/L. It is expected that IGR individuals will 
be identified through a mixture of NHS Health Checks 
and opportunistic or targeted screening processes, and 
that 100 000 individuals will be referred to the DPP each 
year once the programme is running.
Previous economic evaluations indicate that lifestyle 
interventions such as that planned for the NHS DPP 
can be cost-effective.5–8 However, there is evidence that 
diabetes prevention interventions may be differentially 
effective in different population subgroups,9–13 thereby 
potentially leading to differential cost-effectiveness. 
Given the limited number of available interventions, 
analysis of potential disparities in cost-effectiveness of the 
DPP between different subgroups is important not only to 
maximise potential health benefits and cost-savings, but 
also to ensure that health benefits are distributed in the 
population in a fair and equitable manner, which is an 
important consideration for public health interventions.
This study aims to (1) model the potential cost-ef-
fectiveness of the proposed NHS DPP in the English 
population using an adaptation of the National Institute 
for Health Research (NIHR) School for Public Health 
Research (SPHR) Diabetes Prevention Model7 14 and (2) 
investigate in which subgroups, defined by age, gender, 
ethnicity, socioeconomic deprivation, baseline body mass 
index (BMI), baseline HbA1c and working status the DPP 
is likely to have the most benefit in terms of cost-effective-
ness, cost-savings and health benefits.
MethODs
Model structure
The SPHR Diabetes Prevention Model was developed 
to forecast long-term health and healthcare costs under 
alternative scenarios for diabetes prevention. A detailed 
description of the methodology and assumptions used 
in the model can be found in the online supplementary 
appendix 1.
The model is an individual patient simulation model 
based on the evolution of personalised trajectories for 
metabolic factors including BMI, systolic blood pres-
sure (SBP), cholesterol and measures of blood glucose 
(including HbA1c).15 The baseline population consists 
of a representative sample of the English population 
obtained from the Health Survey for England (HSE).16 
HSE 2011 was chosen to inform the baseline population in 
the model due to its focus on diabetes and CVD, meaning 
it incorporates information about relevant metabolic 
factors. Individuals aged <16 years were excluded from 
the analysis.
The model runs in annual cycles (see schematic in the 
supplementary material). For each person, their BMI, 
cholesterol, SBP and HbA1c progress from year to year. 
Every year in the model, an individual may visit their 
general practitioner (GP) or undergo a health check, 
and be diagnosed with and treated for hypertension, high 
cardiovascular risk, diabetes, microvascular complications 
of diabetes, CVD, congestive heart failure, osteoarthritis, 
depression and breast or colon cancer, or may die. Utility 
of each individual in each year of the model is dependent 
on their age, gender and medical conditions. Each condi-
tion is associated with a utility (health-related quality of life) 
decrement and a healthcare cost. Details of how all utilities 
and costs were modelled can be found in the online supple-
mentary appendix. Total costs and quality-adjusted life-years 
(QALYs) are aggregated over all individuals in the model. 
Costs are at 2014 values in English pounds. The model 
perspective is that of the NHS in England.
Intervention
The NHS DPP is an intensive lifestyle intervention 
focusing on dietary advice, physical activity and weight 
loss, aimed at individuals in England at high risk of 
diabetes. The model begins at the point where individ-
uals eligible for the DPP (HbA1c 6%–6.4%/42–47 mmol/
mol; aged ≥16 years) have been identified and does not 
incorporate any local costs or utility change associated 
with identification or referral (see online supplementary 
material details for baseline characteristics for the 1492 
high-risk individuals in the HSE 2011).
An intervention uptake rate of 32% was assumed in 
consultation with PHE. It was assumed that those who 
did not take up the intervention incurred no extra costs 
or benefits. Effectiveness evidence came from a recent 
PHE commissioned evidence review and meta-analysis 
of pragmatic diabetes prevention interventions, carried 
out specifically to inform the likely effectiveness of the 
NHS DPP.9 PHE, NHS England and Diabetes UK have 
specified that in order to maximise intervention effective-
ness, they wish the commissioned DPP to fulfil at least 
9–12 guidelines as recommended in the National Insti-
tute for Health and Care Excellence (NICE) guidance for 
diabetes prevention (PH38).17 NICE guidelines include 
using particular strategies associated with increased effec-
tiveness, specifying the minimum amount of contact time 
and follow-up sessions, and delivering the programme 
through qualified practitioners. In line with this, a 
mean weight loss of 3.24 kg was assumed, taken from the 
meta-analysis of interventions fulfilling 9–12 NICE guide-
lines.9 Data about concomitant reduction in SBP, total 
cholesterol and HbA1c were not available from the PHE 
evidence review and so were linearly extrapolated from 
an earlier review and meta-analysis18 (see supplemen-
tary table S2 and supplementary material for details). 
Current evidence indicates that while there may poten-
tially be a small number of adverse musculoskeletal events 
group.bmj.com on August 22, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
 3Thomas C, et al. BMJ Open 2017;7:e014953. doi:10.1136/bmjopen-2016-014953
Open Access
associated with intensive lifestyle intervention compared 
with control, these are not significant so were not incor-
porated into the analysis.11
There is some evidence to indicate that effectiveness of 
lifestyle interventions to prevent type 2 diabetes differs 
between population subgroups, although study quality 
varies.9–13 Stratification of intervention effectiveness by 
baseline BMI was implemented into the model, again 
using data from the PHE meta-analysis.9 There was 
insufficient evidence around differential effectiveness 
for other subgroups to incorporate into the model. In 
practice, some individuals who start the intervention will 
not complete it. Most of the studies used to derive the 
estimate of effectiveness in the PHE meta-analysis used 
intention-to-treat analysis, but two have not (personal 
communication from N. Ashra). It is likely therefore 
that the effectiveness estimate used in the model only 
partially accounts for non-completion and therefore may 
be higher than is realistic in practice. Sensitivity analysis 
was carried out to account for this possibility. A linear 
rate of weight regain (plus reduction in the intervention 
effects on HbA1c, SBP and cholesterol) was assumed 
over the first five years in line with the assumptions used 
to produce the NICE guidelines for diabetes prevention 
(PH38).19 This meant that individuals’ metabolic trajec-
tories returned to where they would have been without 
intervention, within 5 years of intervention implementa-
tion.
The cost of the NHS DPP was determined through the 
DPP procurement process in 2016. As this was still under-
going at the time of this analysis, the average cost from 
the NHS England impact assessment of £270 per partici-
pant was used.20 This is the price that the NHS is willing 
to pay per person starting the intervention and incorpo-
rates expected retention rates of participants. Due to the 
NHS perspective taken, potential out-of-pocket costs for 
intervention attendees were not included. In the control 
simulation, it was assumed that IGR individuals would not 
receive any intervention and would therefore not incur 
any extra costs or changes to their metabolic trajectories.
subgroups
Population subgroups were selected for analysis due to 
the potential influence of different characteristics on 
diabetes risk and for equity implications. The following 
subgroups were chosen:
 ► four age groups (ages 16–40 years; 40–59 years; 60–
74 years; ≥75 years)
 ► two gender groups (male; female)
 ► two ethnicity groups (white; black minority eth-
nic (BME))
 ► five deprivation groups (index of multiple depriva-
tion (IMD) quintiles 1–5)
 ► three working status groups (working; retired; other)
 ► four BMI groups (BMI<25 kg/m2; 25–29.9 kg/m2; 30–
34.9 kg/m2; ≥35 kg/m2)
 ► two HbA1c groups (HbA1c 6%–6.19%; 6.2%–6.49%).
The analysis models a single year of NHS DPP inter-
vention and all the downstream cost-savings and health 
benefits (including life-years, QALYs and reduction in 
diabetes and CVD cases) that this produces over the 
subsequent 20 years. In total, 1000 model runs were 
performed for each of the 1492 HSE 2011 individuals in 
the deterministic analysis and model outcomes for each 
subgroup extracted from the total results. All costs were 
discounted by 3.5% and QALYs by 1.5%, as per Depart-
ment of Health guidelines.21
sensitivity analysis
Four deterministic one-way sensitivity analyses were 
performed to investigate the sensitivity of the results to 
a more conservative set of intervention parameters. The 
assumptions around intervention specification for each 
of these scenarios are shown in supplementary table S2.
1. uniform intervention effectiveness (no stratification 
by BMI)
2. 25% lower mean effectiveness
3. three-year duration of intervention effect (instead of 
5 years)
4. higher intervention cost of £350 (instead of £270).
A fifth sensitivity analysis was also carried out in which 
a series of combinatorial subgroups were modelled, 
defined by both BMI and age, or BMI and HbA1c, in 
order to observe the interaction between characteristics.
Probabilistic sensitivity analysis (PSA) was carried out to 
describe the uncertainty in parameter inputs of the model 
and how this translates into uncertainty in the outcomes 
of the model. A suitable distribution was selected for 
each parameter, based on its mean and SE. Random 
sampling simultaneously across all input parameter distri-
butions allowed parameter uncertainty to be quantified. 
In total, 5000 different random samples of parameter 
values were selected, and each was applied to the 1492 
individuals in the simulation. A list of model parameters, 
their distribution for PSA and their source is provided in 
online supplementary tables 42-60.
results
Population results
Model results suggest that a year of DPP implementa-
tion in the English IGR population is likely to reduce 
healthcare costs from the first year of implementation, 
recoup intervention costs within 12 years (by the end 
of 2027/2028) and be cost-effective compared with no 
DPP intervention (at a willingness-to-pay threshold of 
£20 000 per QALY gained) within 6 years (by the end of 
2021/2022) (figure 1). For every 100 000 interventions 
given, the DPP is expected to prevent or delay 4147 
cases of diabetes and 413 cases of CVD (table 1).
The subdivision of NHS costs/savings by disease area 
is shown in table 1. This indicates that most cost-savings 
arise due to reductions in the cost of treating diabetes 
or CVD, with high savings also accrued through a 
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Figure 1 Bar charts showing (A) the year that the National Health Service Diabetes Prevention Programme (NHS DPP) 
becomes cost-saving (recoups intervention costs); (B) the year that the NHS DPP becomes cost-effective; (C) the total NHS 
return on investment within 20 years per £1 spent on the NHS DPP for each of the population subgroups. Vertical arrows 
indicate that the DPP is not cost-saving within the 20-year period modelled. BME, black minority ethnic; BMI, body mass index; 
IMD, index of multiple deprivation.
reduction in other primary care costs including GP 
visits and prescription of statins and antihyperten-
sives. The timing of cost-savings varies depending 
on disease area, with cost-savings in CVD care, diag-
nostics and other primary care accumulating in the 
short term, while cost-savings in diabetes treatment, 
microvascular disease and other complications accumu-
late more slowly. This indicates that 1 year of the DPP 
implemented now is likely to continue saving money in 
the NHS for many years in the future despite a fairly 
transient (diminishing over 5 years) effect on meta-
bolic risk factors due to knock-on delays in progression 
to more complex diabetes (requiring insulin) and to 
expensive microvascular complications of diabetes.
Return on investment is calculated by dividing total 
savings or monetised benefit (excluding intervention 
costs) by the cost of the intervention to work out the 
gain obtained for each £1 invested in the DPP. The 
model estimates that at 20 years following intervention 
implementation, for every £1 invested in the DPP, £1.28 
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Total costs £240 £218 £195 £173 £150 £23  –£43 –£75
  DPP costs £270 £270 £270 £270 £270 £270 £270 £270
  NHS costs –£30 –£52 –£75 –£97 –£120 –£247 –£313 –£345
   Diabetes treatment –£1 –£3 –£6 –£9 –£17 –£79 –£106 –£115
   CVD treatment –£11 –£18 –£25 –£32 –£37 –£56 –£65 –£69
   Microvascular 
complications*
–£1 –£3 –£5 –£7 –£10 –£27 –£46 –£60
   Other complications† –£2 –£5 –£8 –£12 –£15 –£30 –£40 –£45
   Diagnostics‡ –£4 –£4 –£5 –£5 –£4 –£3 –£2 –£2
   Other primary care§ –£11 –£19 –£26 –£32 –£37 –£52 –£54 –£54
Life-years¶ 6 41 130 281 486 1795 2838 3487
QALYs¶ 50 133 269 457 686 1986 2966 3552
Diabetes cases¶ −1043 −1995 −3000 −3788 −4147 −1812 −766 −654
CVD cases¶ –183 −273 −344 −396 −413 −394 −325 −282
ICER (£/QALY) £475 625 £163 636 £72 715 £37 870 £21 860 £1162 –£1446 –£2120
Net monetary benefit** –£209 –£138 –£34 £101 £262 £1169 £1822 £2207
RoI: total savings†† £0.11 £0.19 £0.28 £0.36 £0.44 £0.91 £1.16 £1.28
RoI: NMB†† £0.22 £0.49 £0.87 £1.37 £1.97 £5.33 £7.75 £9.17
Costs and cost-ineffective returns are shown in italic whereas savings and cost-effective returns are shown in bold. Costs are discounted at 
3.5% whereas QALYs are discounted at 1.5%.
*Includes costs of nephropathy, ulcer, amputation and retinopathy.
†Includes costs of osteoarthritis, depression, breast and colon cancer.
‡Diagnosis of diabetes, high CVD risk and hypertension.
§Includes costs of GP visits and prescription of statins and anti-hypertensives.
¶Per 100 000 individuals given the DPP intervention.
**Value of a QALY assumed to be £60 000 for net monetary benefit analysis.17
††Return on investment per £1 invested in the DPP.
CVD, cardiovascular disease; DPP, diabetes prevention programme; GP, general practitioner; ICER, incremental cost-effectiveness ratio; NHS, 
National Health Service; NMB, net monetary benefit; RoI, return on investment; QALY, quality-adjusted life-year.
of NHS savings and £9.21 worth of total net monetary 
benefit (calculated using £60 000 as the value of a QALY) 
will be produced (figure 1 and table 1).
subgroup results
Across the subgroup dimensions examined, the biggest 
differentials in cost-effectiveness are seen in the 
subgroups defined by baseline BMI (figure 1). The NHS 
DPP is estimated to be most cost-effective in individuals 
with BMI ≥35 kg/m2 (12% of the eligible population). 
For this subgroup, NHS savings outweigh initial invest-
ment within 5 years and rise to a net value of £520 per 
person within 20 years (figure 2). QALYs gained over 
20 years are also highest (6377 per 100 000 individuals), 
and there are the largest reductions in diabetes and CVD 
cases (maximum reduction of diabetes cases=5484 at year 
6, and maximum reduction of CVD cases=846 at year 
7; see supplementary figure S2). The 20-year return on 
investment is estimated to be £2.93 per £1 spent on inter-
vention (figure 1) and over £17 per £1 spent if monetised 
health benefits are included at £60 000 per QALY. The 
second most cost-saving group is those who have BMI 
30–34 kg/m2. In contrast, the non-obese subgroups have 
substantially worse estimated return on investment, with 
the BMI <25 kg/m2 subgroup not recouping intervention 
costs within the 20-year modelled period.
Across the other dimensions for defining subgroups, 
IMD deprivation quintile makes a relatively small differ-
ence to return on investment. Age makes a much larger 
difference with the middle-age groups (40–59 and 
60–74 years) showing better return on investment than 
the younger (<40 years) and older (≥75 years) groups. 
Estimated return on investment is marginally better for 
females than males, marginally different between working, 
retired and other, and marginally better for a white versus 
BME subgroup. The other large subgroup difference is 
between those above or below 6.2% HbA1c at baseline, 
with the higher HbA1c subgroup showing a larger return 
on investment than the lower HbA1c subgroup.
There are three subgroups to which net mean 
cost-savings do not accrue within the 20 years following 
intervention implementation. These include the oldest 
age group (≥75 years), individuals who are normal weight 
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Figure 2 Graphs showing cumulative incremental (net) costs per person given the intervention over a 20-year time horizon 
for each subgroup and for the total population. Annual incremental costs per person are shown as a dotted line on the total 
population graph. Costs are discounted at 3.5%. BMI, body mass index; DPP, diabetes prevention programme.
or underweight (BMI <25) and individuals with HbA1c 
6–6.19. Note that subgroup characteristics are not mutu-
ally exclusive, so although on average the intervention 
is not cost-saving in people of normal weight, it may be 
cost-saving in certain individuals with other characteris-
tics which correlate with cost-savings, such as high HbA1c.
In general, subgroups that obtain the highest cost-sav-
ings also obtain the highest QALY gains and are the most 
cost-effective as cost-savings relate to preventing disease 
progression. However, the DPP also reduces mortality of 
older individuals, resulting in higher QALYs than might 
otherwise be expected in subgroups containing higher 
numbers of older people. Equally subgroups containing 
younger individuals (including the BME group and the 
most socioeconomically deprived group) gain fewer incre-
mental QALYs and life-years; their disease and mortality 
risk is reduced due to their lower age so the NHS DPP is 
less effective, suggesting that the health benefits of the DPP 
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Figure 3 Probabilistic sensitivity analysis (PSA) results. (A) Cost-effectiveness acceptability curve showing the probability 
that the Diabetes Prevention Programme (DPP) or no intervention will be cost-effective over a range of different willingness-
to-pay thresholds. (B) Distribution of PSA results for (i) the total population and (ii) body mass index (BMI) subgroups on the 
cost-effectiveness plane. Error bars represent 95% CIs for incremental total costs and incremental quality-adjusted life-years 
(QALYs). The cost-effectiveness (CE) threshold is £20 000/QALY. Note that the size of the 95% CIs and therefore the probability 
that the intervention will be cost-effective or cost-saving is partially related to the size of each subgroup within the total impaired 
glucose regulation population of England, in addition to being related to the distribution of results on the cost-effectiveness 
plane.
may not be equitably distributed (see online supplementary 
figures 2 and 3).
In all subgroups, numbers of incremental diabetes/
CVD cases drop in the short term while the intervention 
effect is operating and then rise again at the point when 
weight has been fully regained. This indicates that most 
cases of diabetes/CVD are likely to be delayed rather than 
prevented entirely based on current assumptions about 
long-term effectiveness of the interventions.
sensitivity analyses
The PSA estimation of mean incremental total cost-sav-
ings per person is £131 and of mean incremental QALYs 
is 0.0388 at 20 years following intervention implemen-
tation in England (see online supplementary table 3). 
This is higher for both cost-savings and QALY gains than 
found during deterministic analysis; the difference is due 
to non-linearity in the model, which is likely to be partic-
ularly important around the BMI stratified estimation of 
intervention effect. The probability that the NHS DPP 
will be cost-effective in 20 years compared with no DPP 
intervention, at a willingness-to-pay threshold of £20 000 
per QALY is 97% (see figure 3), and the probability that 
the DPP will be cost-saving for the NHS 20 years after 
intervention implementation is 70%. As in the deter-
ministic analysis, BMI is the most important criteria for 
determining cost-effectiveness, with the two highest BMI 
subgroups being more cost-saving and cost-effective than 
other population subgroups (see online supplementary 
table S3and figure 3).
One-way sensitivity analysis indicates that under conser-
vative scenarios of higher intervention cost (£350 instead 
of £270), 25% lower intervention effectiveness or lower 
duration of intervention effect (3-year decline instead of 
5-year), the NHS DPP would take longer than 20 years 
to recoup initial intervention costs in the majority of 
subgroups (see online supplementary table S4). The inter-
vention is still likely to be cost-effective (at a threshold of 
£20 000 per QALY) within a 10-year time horizon in all 
but the least cost-effective subgroups. Of these scenarios, 
reducing duration of intervention effect has the most signif-
icant impact on outcomes, with only the BMI≥35 subgroup 
remaining cost-saving. However, in all three scenarios, the 
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Figure 4 Graphs showing the interaction between body mass index (BMI) and (A) age, (B) HbA1c. Return on investment in 
combinatorial subgroups defined using two personal characteristics.
relative cost-effectiveness of subgroups remains unchanged 
compared with the base case analysis.
If intervention effect is no longer stratified by BMI, 
the difference between subgroups of a particular popu-
lation characteristic is reduced compared with the base 
case scenario. While for some subgroups, such as those 
defined by BMI, a clear gradient is still apparent, for other 
groups such as those defined by IMD quintile or ethnicity 
the difference in outcomes is minimal, suggesting that 
stratification of intervention effectiveness by BMI is a key 
driver of differential cost-effectiveness in those groups in 
the base case analysis.
Combinatorial analysis indicates that the high return on 
investment in the BMI 35+ subgroup is mitigated in indi-
viduals who are also aged 75+ and reduced to only £1.54 
per £1 spent, whereas in individuals aged 40–59 years it 
is improved even further to £3.20 (figure 4). An even 
higher return on investment of £3.52 could potentially 
be obtained if individuals who have both BMI 35+ and 
HbA1c 6.2%–6.4% are selected for the NHS DPP inter-
vention. This suggests that subgroups with high benefits 
can be combined to potentially increase the return on 
investment even further.
DIscussIOn
It is essential with large-scale and expensive national 
programmes such as the NHS DPP that a cost-effectiveness 
analysis using the best currently available data is carried 
out prior to implementation: first, to determine whether 
the intervention should be carried out at all; second, to 
enable effective budgeting; and third, where interven-
tions are limited, to estimate who is likely to benefit most 
and therefore should be prioritised. This analysis suggests 
that the NHS DPP is highly likely to be cost-effective and 
cost-saving over the medium to long term using current 
assumptions around intervention cost, effectiveness and 
duration of effect, and should start to save costs for the 
NHS from the first year of implementation, recouping 
the initial investment in the intervention by year 12. The 
number of potential individuals at high risk of type 2 
diabetes in England (estimated to be about 5 million2) 
far exceeds the 100 000 interventions that NHS England 
plans to offer each year.3 This analysis indicates that prior-
itising obese individuals in particular (BMI ≥30 kg/m2), 
combined with those with the highest baseline HbA1c and 
focusing on those aged between 40 and 74 years (the ages 
covered in any case by the NHS Health Check), is likely 
to create the most value for money in the programme by 
obtaining both the greatest cost-savings for the NHS and 
the highest health benefits per individual targeted.
This study does suggest that care may have to be taken 
when implementing the NHS DPP to ensure that it does 
not lead to greater health inequalities in some groups 
at high risk of type 2 diabetes and its complications, 
including individuals from minority ethnic or socioeco-
nomically deprived backgrounds. The analysis shows a 
tendency for the NHS DPP to provide fewer QALYs to 
these subgroups than to individuals from more socio-
economically advantaged or white ethnic backgrounds. 
Given that the model does not incorporate (nor is there 
any clear evidence for) differential effectiveness of the 
NHS DPP by socioeconomic status or ethnicity, these 
differences are likely to occur for two main reasons. First, 
disease risk is influenced by subgroup; for example, both 
ethnicity and socioeconomic status are parameters in the 
QRISK equations that are used in the model to determine 
CVD risk.22 This means that even if a given individual 
reduces their metabolic risk factors through the DPP they 
may still be at high risk of disease due to environmental 
or genetic factors outside the scope of the intervention. 
Second, subgroups differ in key personal characteristics 
associated with intervention efficacy; for example, mean 
age is lower than average in the BME subgroup and in the 
most socioeconomically deprived quintile. Low mean age 
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results in lower health benefits and return on investment 
from the NHS DPP than high age due to the lower abso-
lute risks of disease and mortality in such individuals and 
therefore lower ability to benefit. Given that BME and low 
socioeconomic status subgroups also tend to suffer from 
low uptake of lifestyle interventions,23 24 it is important 
that NHS DPP providers make particular efforts to engage 
individuals from these groups if exacerbation of health 
inequalities is to be avoided.
A major strength of this analysis is the synthesis of a 
broad range of evidence using the SPHR Diabetes Preven-
tion Model.7 14 This is an individual patient simulation 
model that incorporates a large amount of evidence from 
published data about type 2 diabetes risk factors and the 
complex disease progression pathways that lead from a 
diabetes diagnosis and is able to represent the heteroge-
neity present within the English population and thereby 
model population subgroups. However, the model only 
takes healthcare costs into account, meaning that wider 
societal costs and benefits cannot be calculated, and even 
within healthcare does not incorporate diseases such as 
dementia that may impact on long-term healthcare costs. 
A more important limitation is that the comparator of 
‘no NHS DPP intervention’ used for this analysis does not 
fully represent the current situation where some localities 
do have programmes for high-risk individuals. These were 
not modelled due to limited evidence and heterogeneity of 
intervention implementation between localities. Subgroup 
analysis has also been limited by the relatively small number 
of IGR individuals in the HSE data, meaning that smaller 
subgroups (such as individual minority ethnic groups) or 
a larger variety of subgroup combinations, both of which 
would provide useful information for those implementing 
the NHS DPP, cannot be accurately modelled.
While this study is not based on actual clinical data 
from the NHS DPP, because such data does not yet 
exist as the national programme implementation is just 
beginning, it does use the most recently published esti-
mates of intervention effectiveness from a PHE evidence 
review designed specifically to inform the development 
of the NHS DPP,9 and therefore is likely to provide a 
more accurate estimate of NHS DPP cost-effectiveness 
than previous economic analyses of diabetes prevention 
interventions. However, data about the long-term effec-
tiveness of lifestyle interventions and the differential 
response of population subgroups to such interventions 
is limited and represents the most important limitation 
of this study. Deterministic sensitivity analysis indicates 
that the cost-effectiveness of the NHS DPP is substantially 
influenced by parameters such as intervention effective-
ness and duration of intervention effect, which could also 
impact on the ordering of subgroups. Future research 
should therefore focus primarily on improving estimates 
of subgroup effectiveness, and gathering evidence about 
initial weight loss and weight regain rates due to the NHS 
DPP, which could be added to the model. The biggest 
challenges in performing good quality subgroup analysis 
are sufficiently powering the clinical studies to account 
for subgroups that may only comprise a small propor-
tion of the population, and taking into account potential 
interaction between personal characteristics that could 
lead to confounding across subgroups in intervention 
uptake rates or effectiveness. The NIHR is commissioning 
a formal evaluation of the NHS DPP which will include 
cost-effectiveness analysis. Careful statistical design of this 
analysis and long-term follow-up of participants should 
enable these challenges to be overcome successfully and 
provide high-quality data for updating and improving the 
accuracy of model predictions.
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